RecruitingPhase 1NCT06699771

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Studying Lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
GC Cell Corporation
Intervention
GCC2005(drug)
Enrollment
48 target
Eligibility
19-80 years · All sexes
Timeline
20252027

Study locations (3)

Collaborators

Artiva Biotherapeutics, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06699771 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma

← Back to all trials